Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Andre

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2018
Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trialM Arnedos, M A Bayar, B Cheaib, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscapeD J Vis, J Lewin, R G Liao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2012
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclassesW E Pierceall, K A Olaussen, V Rousseau, et al.
ESMO Open|May 16, 2025
Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO)A-S Hamy, B Grandal, F Jochum, et al.
ESMO Open|April 16, 2025
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trialM Saint-Ghislain, S Chabaud, F Dalenc, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2022
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patientsJ Chen, F Facchinetti, F Braye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancersJ van de Haar, P Roepman, F Andre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancerA Mamann, Y Pradat, F C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2019
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysisA R Ferreira, A Di Meglio, B Pistilli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2018
Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trialM Arnedos, M A Bayar, B Cheaib, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscapeD J Vis, J Lewin, R G Liao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2012
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclassesW E Pierceall, K A Olaussen, V Rousseau, et al.
ESMO Open|May 16, 2025
Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO)A-S Hamy, B Grandal, F Jochum, et al.
ESMO Open|April 16, 2025
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trialM Saint-Ghislain, S Chabaud, F Dalenc, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2022
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patientsJ Chen, F Facchinetti, F Braye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancersJ van de Haar, P Roepman, F Andre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancerA Mamann, Y Pradat, F C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2019
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysisA R Ferreira, A Di Meglio, B Pistilli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
Pageof 12